Nav: Home

Biologists discover source for boosting tumor cell drug sensitivity

October 29, 2018

DNA-damaging agents, or "DDAs," make up the most widely used group of cancer drugs. Yet their therapeutic success has been curtailed by drug resistance--either present in cancer cells from the disease onset or arising during treatment.

Now, biologists at the University of California San Diego have discovered a new way of re-sensitizing drug-resistant human tumor cells to the potency of DDAs.

UC San Diego Project Scientist Manqing Li, Professor Michael David and their colleagues describe on October 29 in Nature Structural and Molecular Biology how a human gene known as Schlafen 11 controls the sensitivity of tumor cells to DDAs. As such, their research may pave the way to new strategies to overcome chemotherapeutic drug resistance.

In 1998, David Schwarz, working in UC San Diego Biological Sciences Professor Stephen Hedrick's lab, discovered the first Schlafen gene in mice. He named it for the German word for sleep because the gene's protein product can cause cells to stop dividing. In 2012 David and Li examined Schlafen 11, a human genetic counterpart of the original discovery, and uncovered its role in HIV replication. They found that the human Schlafen 11 gene encodes a protein that hinders the replication of HIV in infected human cells by blocking the synthesis of viral proteins without suppressing the host cell's overall ability to synthesize proteins.

In the new follow-on study focusing on tumors, the researchers discovered a similar selective effect of Schlafen 11 on two "master controllers" of the DNA damage response: ATM and ATR, protein serine/threonine kinases known for their central roles in DNA damage repair.

"We found that if you expose cells that have Schlafen 11to DNA damaging agents, the Schlafen 11 protein gets activated and suppresses the synthesis of ATM and ATR--that's essentially what kills the tumor cells," said David, a professor in the Biological Sciences Section of Molecular Biology and UC San Diego Moores Cancer Center. "In cells that do not express Schlafen 11, you do not get this downregulation of ATM/ATR and that essentially allows the tumor cells to survive."

Probing deeper into the mechanisms of how Schlafen 11 works on a molecular level, the researchers found that the activated Schlafen 11 protein cleaves a specific subset of transfer RNAs, which feature an extra stem loop in their structures. These tRNAs are not of the classic "three-leaf clover"-type design, but instead have distinctive "four-leaf clover" designs, distinguishing marks that likely serve as target points for Schlafen 11. Among those affected are all transfer RNAs for the amino acids leucine and serine. One of these in particular, "tRNA-Leu-TAA," is of extremely low abundance in the cell, but nevertheless the corresponding codon is used with high frequency in the ATM and ATR genes. When this tRNA is destroyed by cleavage, ATM and ATR are among the most susceptible targets of protein synthesis inhibition by Schlafen 11.

Further investigation revealed that most of the genes involved in DNA damage repair display a similar skewing of their transfer RNA use towards tRNA-Leu-TAA as HIV does. The researchers then developed a new technique to re-sensitize Schlafen 11-deficient tumor cells to drugs by directly targeting tRNA-Leu-TAA. This intervention can influence the entire DNA damage repair pathway-- including ATM and ATR--rather than inhibiting the function of one specific component at a time. Such a strategy, they say, could have significant potential in clinical cancer treatment and addressing the challenges of drug resistance.

Study coauthor Jean Wang, professor emeritus in UC San Diego's School of Medicine, says knowing how cancer cells escape death when their DNA is damaged will create new strategies to enhance cancer cell killing through chemotherapy treatment.

"These results suggest two ways to enhance the killing of cancer cells by DNA-damaging drugs by adding 1) ATR inhibitors or 2) tRNA inhibitors," said Wang. "The paper is also of significance to the basic research on DNA damage response because it shows for the first time that regulation of tRNAs determines when a damaged cell will survive or die."

In addition to relevance to DNA damage and cancer, David notes that the new results carry potential applications in immunology and virology since the fundamental mechanisms behind Schlafen 11 are also at play in anti-HIV processes and likely with other viruses.
-end-
David acknowledges the significant contributions of co-first authors Elaine Kao and Dane Malone, as well as to Xia Gao, of UC San Diego's Division of Biological Sciences, and Wang, professor emeritus of the Department of Medicine and UC San Diego Moores Cancer Center.

University of California - San Diego

Related Cancer Articles:

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
Health indicators for newborns of breast cancer survivors may vary by cancer type
In a study published in the International Journal of Cancer, researchers from the UNC Lineberger Comprehensive Cancer Center analyzed health indicators for children born to young breast cancer survivors in North Carolina.
Few women with history of breast cancer and ovarian cancer take a recommended genetic test
More than 80 percent of women living with a history of breast or ovarian cancer at high-risk of having a gene mutation have never taken the test that can detect it.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Speedy Beet
There are few musical moments more well-worn than the first four notes of Beethoven's Fifth Symphony. But in this short, we find out that Beethoven might have made a last-ditch effort to keep his music from ever feeling familiar, to keep pushing his listeners to a kind of psychological limit. Big thanks to our Brooklyn Philharmonic musicians: Deborah Buck and Suzy Perelman on violin, Arash Amini on cello, and Ah Ling Neu on viola. And check out The First Four Notes, Matthew Guerrieri's book on Beethoven's Fifth. Support Radiolab today at Radiolab.org/donate.